Neonatal whole genome sequencing: clinical promise and ethical tensions

Whole genome sequencing has shifted from a research tool to a clinical reality in perinatal medicine, with turnaround times now measured in days rather than months. In neonatal intensive care units across Sydney, Melbourne, Brisbane and Perth, rapid genomic testing is increasingly being used to shorten the diagnostic odyssey for babies born with unexplained illness. For families and clinicians alike, the technology raises questions that go well beyond the laboratory: what should be sequenced, what should be reported, who pays, and how is consent meaningful when a newborn is only hours old?

The Australian context matters here. The Australian Genomics Health Alliance has run several flagship programs evaluating genomic testing in acute paediatric care, and the Murdoch Children's Research Institute in Melbourne has been a key contributor to international evidence on rapid sequencing in the NICU. These initiatives, alongside Medicare funding for some genetic tests, mean Australian families are more likely than those in many neighbouring countries to access public-sector sequencing. Yet the policy and ethical frameworks have not always kept pace with the science, leaving clinicians and parents to navigate complexity at the bedside.

Why rapid sequencing is changing neonatal care

For a critically unwell newborn, every hour can matter. Traditional diagnostic pathways often involve a cascade of single-gene tests, biochemical screens and imaging before a unifying diagnosis emerges. Rapid whole genome sequencing compresses much of that pathway into a single assay, with provisional results sometimes available within forty-eight hours. Australian paediatric studies have reported diagnostic yields of around forty to fifty per cent in selected NICU cohorts, which is a remarkable figure when compared with conventional testing.

The benefit is not only clinical. A timely molecular diagnosis can spare a family months of uncertainty, redirect care away from interventions that are unlikely to help, and in some cases enable access to targeted therapies or clinical trials. In a country as geographically dispersed as Australia, this matters particularly for families in regional centres like Townsville, Cairns or Hobart, where repeated transfers to a tertiary children's hospital can be logistically and emotionally costly. Genetic counsellors based at services such as the Victorian Clinical Genetics Services increasingly support these families through telehealth, which has become routine practice since the pandemic.

The case for sequencing is therefore compelling, but it depends on something the technology itself cannot provide: a thoughtful clinical and ethical process around its use.

Consent in the perinatal window

Informed consent is the cornerstone of any genomic test, yet the perinatal setting makes it unusually difficult. Parents are typically exhausted, frightened, and trying to absorb unfamiliar medical terminology while their baby is in a humidicrib. The standard of consent expected by the National Health and Medical Research Council and the Australian Health Ethics Committee does not drop in these circumstances; if anything, the burden on clinicians to communicate clearly is higher.

Pre-test counselling should ideally cover the scope of the test, the possibility of incidental findings, the implications for future pregnancies, and the family's right to decline. In practice, this conversation may happen in snippets over several days rather than as a single formal session. Genetic counsellors, working alongside neonatologists, play a central role in ensuring parents understand what they are agreeing to. Where English is not a first language, or where cultural frameworks around disability and inheritance differ from the clinician's own, interpreters and cultural liaison officers become essential rather than optional.

There is also a question of consent for the child's future. A genome generated today will remain informative for decades, yet the infant cannot consent to its storage, secondary use or future reanalysis. Some Australian services address this by storing data only with explicit parental consent for re-contact, while others limit access to the treating clinical team. The diversity of these models reflects an underlying tension: how to honour parental authority while preserving the future autonomy of the child.

Incidental findings and the right not to know

Whole genome sequencing does not return only the answers a clinician asks for. Depending on the analysis pipeline, it can surface pathogenic variants associated with adult-onset conditions such as BRCA-related cancers, Huntington's disease, or cardiac arrhythmias. Whether these findings should be disclosed to parents on behalf of the newborn is one of the most debated questions in clinical genomics.

The Australian position, broadly aligned with international practice, distinguishes between childhood-onset actionable findings, which are usually reported, and adult-onset variants, which are generally not disclosed unless specifically requested. This pragmatic compromise respects the future autonomy of the child while giving parents information that could affect siblings or extended family. Yet many parents find the distinction counterintuitive and ask why a clearly harmful variant should be hidden simply because the disease will not appear for thirty years.

The question becomes sharper in culturally diverse communities, where family-based disclosure norms may differ from the individual-autonomy model embedded in Australian bioethics. Some families will want everything; others will want nothing beyond the immediate clinical question. A robust service needs the capacity to honour both, and to revisit the conversation as the child grows.

Equity of access across the country

Australia's universal healthcare system, Medicare, underwrites many genetic tests, but the rebate schedules have not always kept up with the cost of whole genome sequencing. Private health funds vary in their coverage, and out-of-pocket costs can run into thousands of dollars for families whose child is not eligible for a public-sector rapid sequencing program. The result is a postcode lottery, with access concentrated in major metropolitan children's hospitals and limited in rural and remote areas.

For Aboriginal and Torres Strait Islander families, there are additional considerations. Data sovereignty, the principle that communities retain control over genomic data derived from their members, is a live policy issue, and the governance arrangements around any sequencing program need to reflect this. Trusted intermediaries, including Aboriginal Community Controlled Health Organisations, are increasingly recognised as essential partners rather than optional consultants.

Telehealth has helped narrow the geographic gap, but it cannot replace the value of face-to-face genetic counselling at moments of acute distress. Sustained funding for regional genetic services, alongside equitable reimbursement for genomic tests, will determine whether rapid sequencing becomes a standard of neonatal care or remains a privilege of the few. The Australian government's recent moves towards broader reimbursement of pharmacogenomic and exome-based tests suggest the direction of travel, though whole genome sequencing still sits in a contested middle ground.

Governance, workforce and laboratory quality

Embedding neonatal whole genome sequencing into routine care requires more than a sequencing machine. It demands accredited laboratories, consistent variant interpretation, secure data infrastructure, and a workforce trained to communicate results responsibly. The Royal College of Pathologists of Australasia, working with international bodies, sets laboratory standards, while clinical interpretation is increasingly supported by multidisciplinary team meetings that mirror tumour board practice in paediatric oncology.

Workforce capacity is a quiet constraint. The number of clinical geneticists and genetic counsellors in Australia is small relative to demand, and most are concentrated in capital cities. Training pipelines are expanding, including through the University of Technology Sydney and the University of Melbourne, but the gap between supply and clinical need remains significant. Without deliberate investment in people, the infrastructure investment risks being underused.

Finally, governance frameworks need to keep pace with the technology. The National Health and Medical Research Council's principles for the use of genetic information, alongside state-level privacy legislation, provide a starting point. The international nature of genomic databases, the use of cloud-based pipelines, and the growing role of machine-learning variant classifiers all raise questions that national regulation alone cannot answer. Collaborative forums convened through regional perinatal societies have an ongoing role in bringing clinicians, scientists and ethicists together to navigate these shared challenges.

Comparison of sequencing approaches in neonatal care

Principles to guide a neonatal sequencing service

• Treat the genome as a lifelong resource belonging to the child, not a one-off diagnostic test.
• Distinguish actionable childhood-onset findings from adult-onset variants and respect parental choices on disclosure.
• Use multidisciplinary teams, including genetic counsellors and clinical geneticists, for every result returned.
• Build culturally safe pathways for Aboriginal and Torres Strait Islander families and other communities underrepresented in genomic datasets.

Practical considerations for clinicians offering testing

• Confirm pre-test counselling has covered incidental findings, data storage and implications for relatives.
• Verify the laboratory's accreditation status and the version of the variant interpretation pipeline.
• Discuss cost and likely out-of-pocket expenses openly before the sample is drawn.
• Plan for reanalysis at twelve to twenty-four months, as new gene-disease associations emerge regularly.

For clinicians, researchers and policymakers working at the intersection of perinatal medicine and genomics, ongoing dialogue across the region is essential. Conversations begun at gatherings such as the https://faops2020.com/ initiative continue to shape how neonatal sequencing is offered, governed and explained to families, and bringing Australian experience to those conversations is how the field will mature into a service that is clinically rigorous, ethically defensible and genuinely accessible to every family that needs it.